HK1209758A1 - Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies i(ifnar) - Google Patents

Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies i(ifnar)

Info

Publication number
HK1209758A1
HK1209758A1 HK15110286.5A HK15110286A HK1209758A1 HK 1209758 A1 HK1209758 A1 HK 1209758A1 HK 15110286 A HK15110286 A HK 15110286A HK 1209758 A1 HK1209758 A1 HK 1209758A1
Authority
HK
Hong Kong
Prior art keywords
ifnar
antibodies
type
dosage regimens
interferon receptor
Prior art date
Application number
HK15110286.5A
Other languages
English (en)
Chinese (zh)
Inventor
Brandon Higgs
Yihong Yao
Bing Wang
Lorin Roskos
Linda Chang
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49758685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1209758(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of HK1209758A1 publication Critical patent/HK1209758A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Data Mining & Analysis (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Databases & Information Systems (AREA)
  • Theoretical Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Primary Health Care (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Mathematical Optimization (AREA)
  • Computational Mathematics (AREA)
HK15110286.5A 2012-06-13 2015-10-20 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies i(ifnar) HK1209758A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261659138P 2012-06-13 2012-06-13
PCT/US2013/045327 WO2013188494A1 (en) 2012-06-13 2013-06-12 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies

Publications (1)

Publication Number Publication Date
HK1209758A1 true HK1209758A1 (en) 2016-04-08

Family

ID=49758685

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110286.5A HK1209758A1 (en) 2012-06-13 2015-10-20 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies i(ifnar)

Country Status (9)

Country Link
US (1) US9493570B2 (xx)
EP (1) EP2861621A4 (xx)
JP (5) JP2015526391A (xx)
KR (3) KR102320059B1 (xx)
CN (3) CN111494624A (xx)
AU (3) AU2013274389A1 (xx)
CA (1) CA2876636C (xx)
HK (1) HK1209758A1 (xx)
WO (1) WO2013188494A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100680048B1 (ko) * 2006-01-23 2007-02-08 쌍용자동차 주식회사 자동차 도장용 크레인의 구조
US20180305761A1 (en) * 2015-10-09 2018-10-25 Genefron Ltd. METHODS AND KITS FOR PREDICTION AND DIAGNOSIS OF HUMAN CYTOMEGALOVIRUS (hCMV) CONGENITAL TRANSMISSION
HRP20240603T1 (hr) 2016-07-01 2024-07-19 Resolve Therapeutics, Llc Optimizirane fuzije binukleaze i postupci njihove upotrebe
CN106243226B (zh) * 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
EP3601352B1 (en) 2017-03-21 2021-02-17 Austrianni GmbH Type 1 interferon receptor antagonists for use in methods of treating tuberculosis and other infectious diseases
CN111315767A (zh) 2017-08-22 2020-06-19 萨纳生物有限责任公司 可溶性干扰素受体及其用途
KR20210084528A (ko) 2018-10-26 2021-07-07 얀센 바이오테크 인코포레이티드 I형 인터페론 시그너처 및 사용 방법
CN115925950A (zh) * 2019-01-31 2023-04-07 广东旋玉健康生物科技有限公司 新型抗ifnar1抗体
CN111892653A (zh) * 2019-07-03 2020-11-06 长春恒晓生物科技有限责任公司 制备粘病毒抗性蛋白1抗体及建立检测mx1方法
WO2022223771A1 (en) 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
JP7484027B2 (ja) * 2021-04-23 2024-05-15 アストラゼネカ・アクチエボラーグ 皮下注射のための抗ｉｆｎａｒ１投薬計画

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002322478A1 (en) * 2001-03-02 2002-12-16 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
PL1781705T3 (pl) * 2004-06-21 2015-03-31 Squibb & Sons Llc Antyciała receptora interferonów alfa I oraz ich zastosowania
WO2006128210A1 (en) * 2005-06-03 2006-12-07 John Arthur Notaras A tiller
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
EP2037966A2 (en) * 2006-05-11 2009-03-25 Ghent University Sialoadhesin-related compositions and methods
CN101594882A (zh) * 2006-12-06 2009-12-02 米迪缪尼有限公司 干扰素α诱导的药代动力学标记物
BRPI0720035A2 (pt) * 2006-12-06 2019-05-07 Medimmune, Llc métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit
AU2008324800B2 (en) * 2007-11-05 2014-03-27 Astrazeneca Ab Methods of treating scleroderma
CA2713981C (en) * 2008-02-08 2016-11-01 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
US20110287022A1 (en) * 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
EP2318548B1 (en) * 2008-08-15 2013-10-16 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
WO2011028933A1 (en) 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic

Also Published As

Publication number Publication date
AU2020204613B2 (en) 2021-10-07
EP2861621A4 (en) 2016-01-20
AU2018206851B2 (en) 2020-07-30
KR20150035825A (ko) 2015-04-07
WO2013188494A1 (en) 2013-12-19
AU2013274389A1 (en) 2015-01-22
KR102185237B1 (ko) 2020-12-02
KR102320059B1 (ko) 2021-11-01
JP2021042208A (ja) 2021-03-18
US20150158949A1 (en) 2015-06-11
JP7123225B2 (ja) 2022-08-22
JP2021167336A (ja) 2021-10-21
JP6814238B2 (ja) 2021-01-13
AU2018206851A1 (en) 2018-08-09
EP2861621A1 (en) 2015-04-22
AU2020204613A1 (en) 2020-07-30
AU2018206851C1 (en) 2021-11-25
KR20210130270A (ko) 2021-10-29
US9493570B2 (en) 2016-11-15
JP2019112429A (ja) 2019-07-11
JP2018065845A (ja) 2018-04-26
CN108310375A (zh) 2018-07-24
CN104603152A (zh) 2015-05-06
CA2876636A1 (en) 2013-12-19
KR20200133395A (ko) 2020-11-27
CA2876636C (en) 2022-09-13
KR102185237B9 (ko) 2021-08-06
CN111494624A (zh) 2020-08-07
JP2015526391A (ja) 2015-09-10

Similar Documents

Publication Publication Date Title
HK1209758A1 (en) Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies i(ifnar)
HK1207316A1 (en) Anti-prolactin receptor antibody formulations
HK1203191A1 (en) P2x4 receptor antagonist p2x4
HK1203560A1 (en) Modified polypeptides for bispecific antibody scaffolds
IL227853A0 (en) A test for detecting autoantibodies to anti-tnfα drugs
EP2846798A4 (en) ALIPHATIC SPIROLACTAM-CGRP RECEPTOR ANTAGONISTS
HK1203938A1 (en) Novel 2h-indazoles as ep2 receptor antagonists ep2 2h-
EP2771069A4 (en) INHIBITION OF POLYPEPTIDES FROM 6-G PROTEIN-COUPLED RECEPTOR RECEPTORS
HK1192228A1 (zh) 受體拮抗劑
PT2714661E (pt) Derivados de ácido picolinamido propanóico úteis como antagonistas do recetor de glucagona
PT2793942T (pt) Novas composições farmacêuticas compreendendo um anticorpo que liga o recetor humano da hormona anti-mulleriana de tipo ii
ZA201403245B (en) Process for the preparation of an endothelin receptor antagonist
EP2714083A4 (en) RATIONAL-DESIGNED TYPE II RECEPTOR ANTIBODIES WITH A MULLERIAN-INHIBITABLE SUBSTANCE
BR112015005750A2 (pt) antagonistas peptídicos do receptor de vasopressina-2
FI20125038A (fi) Endoteliinireseptorin vastavaikuttajan valmistusprosessi